see Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

  1. 11/15/11 11/15/11 -
  2. 3/23/14 3/23/14 - Martin Dugas
  3. 8/10/14 8/10/14 - Martin Dugas
  4. 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
  5. 9/20/21 9/20/21 -
  6. 9/28/21 9/28/21 - Sarah Riepenhausen
Copyright Holder:
Uploaded on:

September 28, 2021

To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00005404 NCT00617669 Prostate Cancer

Eligibility NCT00617669

  1. StudyEvent: Eligibility
    1. Eligibility NCT00617669
Inclusion Criteria
Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastasis)
Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
Currently receiving treatment with surgical or medical castration
Exclusion Criteria
Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial
Suffering from heart failure or had a myocardial infarction within last 6 months
A history of epilepsy or seizures

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial